Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.
Marc Wortman
The blood-brain barrier gets no respect. It should. Fewer than 2% of drugs have the requisite properties to get across...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
